

With a vision to cure and a mission to care, we are committed to improving the quality of life for patients and their families living with leukaemia, lymphoma, myeloma, and related blood conditions.



Leukaemia & Blood Cancer Research Unit (LBCRU)

Contents

Our Values	3
CEO's Report	4
Chair's Report	5
Our Objectives	6
Numbers Snapshot	7
Objective 1 - Support	8
Objective 2 - Research	10
Objective 3 - Advocacy	12
Objective 4 - Sustainability	14
Financial snapshot	18
Supporters	19

Our Values

Vision to Cure
.....
Mission to Care

Respect It We're mindful of our actions & communications while valuing every person's role

Own It We take responsibility, professional pride, & strive for continuous improvement

Care for It We're considerate, supportive and compassionate, both internally & externally

Show It We walk the walk & show what LBC stands for every day

Our Mission to Care stays true no matter what

> Peter Fergusson

Chief Executive Officer, Leukaemia & Blood Cancer New Zealand



Operationally the 2021/22 year was, in sporting terms, a 'game of two halves'. 2021 dawned with the euphoria of, what appeared to be, reducing COVID-19 impacts, and for the first half of that year, a level of nervous normality returned. Events took place, funding channels returned, research and 'face-to-face' patient support services resumed earnestly. Alongside many great learnings, we continued to develop better uses of technology and drove innovative improvements within the organisation.

The second half of 2021 (into 2022) saw the return of more significant infection, stricter lockdowns and border controls, which again called on everyone's resilience.

With those challenges in mind, there are five key groups of people I want to recognise:

- **Our patients (and families)** – the difficulties, concerns and disruption you endure are magnified, in this environment, beyond belief – stay positive and stay strong.
- **Our committed sponsors** – despite their own challenges, these businesses have unconditionally continued to show their support to LBC (and our patients) – thank you.
- **Our donors** – Kiwi's traditionally shine, as a nation, when times are tough. Once again, our donors have continued and increased their support of LBC in a time of need.
- **Our LBC Board** – the steady and calm leadership given throughout the past year(s) has been the bedrock to making key and informed decisions.
- **Our LBC staff** – the enormous efforts, passion and commitment needed to re-plan, re-work, re-create and re-imagine how services and support could continue for patients, research continued, and much-needed funding gained and replaced; this was nothing short of miraculous – thanks, team.

I am proud to present the stories of real impact, outcomes and achievements within this report.

A handwritten signature in black ink, appearing to be 'Peter Fergusson'.

Peter Fergusson, Chief Executive Officer

Maintaining peak performance in a changing world

> Pene Milne

Chair, Leukaemia & Blood Cancer New Zealand



Like all organisations (NGO or otherwise) LBC operates in an environment of constant change. What will the future become and look like? What does this mean for an organisation not reliant on government support?

Good governance must support all staff to the best they can be to provide the foundation for a high-performing organisation. Ensuring the collective mission (to care) and vision (to cure), we know systems must be invested in and driven to succeed.

Here are some of the key areas we as a Board constantly review;

- **Technology** - has transformed business, and investment in this area is critical. It is changing very rapidly, whether how a bone marrow donor gift is transported here from a distant part of the globe to save a life, or the research collaborations that are saving lives every day. It is vital we communicate clearly across generations.
- **A Voice** - we know our stakeholders and clients need and rely upon us to be a voice at the right time, in the right place, and bring advocacy to the working table, with whom, when, and why.
- **Care and Cure** – audacious goal setting means that as we start to live with rather than die from blood cancers, increased investment in leading local and global research programmes is critical to be able to provide certainty to those undertaking it and divested so heavily in outcomes.
- **Survivorship** – there is a responsibility to the growth of the endowment fund for ensuring the work of LBC for care and cure is certain.

As Chair, I am excited. We see new opportunities in local and global collaborations, growth in our staff and therefore reach, and importantly, a focus on better lives.

A handwritten signature in black ink that reads "Pene Milne". The script is fluid and cursive.

Pene Milne, Chair

Our Objectives



THANK YOU TO ALL OF OUR WONDERFUL PARTNERS



Our Numbers snapshot

Total number of referrals



1,082

\$647,988



Total patient related financial support

Total amount given to research



\$476,614

4,904



Total number of patients supported

2022 Website analytics

86,013

Information pages viewed for those wanting information on conditions

174,883

Total visits to www.leukaemia.org.nz



11,145

Support pages viewed for those needing support of LBC

Objective

1

Support

Embracing change, fast

With a sudden nationwide lockdown and only 2 weeks until LBC's Blood Cancer Patient Forum, we had to work fast to turn this event into a fully online operation. Our fantastic line up of 20 topics from expert speakers in the Haematology and supportive care field was kept intact with a streamlined online programme run by the entire Support Services team across the 2 days.

Webinars were recorded for those who could not get to all the talks, extending our reach across Aotearoa and enabling more people to tune in. The event was extremely successful with over two hundred attendees on the day as well as over 3000 views on YouTube of the recorded talks. David Downs and members from LBC's Consumer Advisory Board opened the event, followed by a range of talks about living optimally with a blood cancer – from managing late effects to tips on increasing energy levels.

Highlights included Dr Robert Weinkove's talk on Haematology and the COVID landscape, Professor Peter Browett and Professor Ian Morison's talk on Genes, Genetics & Familial Blood Cancers, Dr Richard Doocey on Navigating Access to Unfunded Drugs, Dr Graeme Kidd on Self-empowerment and living well with blood cancer and Dr Myra Ruka on Updates and Activities at Te Aho o Te Kahu, the Cancer Control Agency.



Dr Robert Weinkove

“ We are grateful to the ANZ Staff Foundation for their support, which ensured the Forum went ahead. ”

Blood Cancer Patient Forum

3,024 Views

20 Videos

Dr. Rob Weinkove COVID-19 lockdown videos


7,338 Views

9 Videos

Overall Youtube stats

442,406 Views

516 New subscribers during the year



Kids' Zone – how it came to be



Young member of Super Kids' Club helping to inspire the design of the new logo

We have created a space for children and their families affected by blood cancer or a serious blood condition. LBC offers a range of services and programmes to support our paediatric patients, their siblings, as well as the children of patients. We wanted a fun zone that was clear, helpful and engaging for everyone.



The Kids' Zone includes:

- Kids' Club
- Kids' Club online
- Super Kids' Club
- Resources and support for parents
- Helpful books for big worries
- Monkey In My Chair
- Battle Bus Bonanza

Meeting important needs

With the ongoing challenge of COVID-19 and lockdowns, the LBC Support Services team found new and creative ways to continue to meet the needs of the patients and families.

We moved our services online with increased phone calls, online groups, webinars and information material, and made sure we reached out regularly to our most vulnerable patients.

We increased our financial support with more grocery and petrol vouchers and found ways to ensure patients still got to treatment.

With an extra need for mental health support this year, we built this into our service provision and increased our counselling support.



Moved critical services online



Increased financial support



Mental health support

A focus for the patients was staying safe during COVID-19, so we ensured they were kept informed with webinars and updates.

Objective

2

Research

Today's research, tomorrow's cure

In 2021, LBC's Medical & Scientific Committee awarded 3 grants totalling over **\$163,000**. Two of these went to research projects at the University of Otago, reflecting the national focus we have for haematology research.

Both recipients are senior researchers and collaborators at the university. However, their diverse choice of subjects show the depth of research currently taking place in New Zealand.

Associate Professor Liz Ledgerwood from the Department of Biochemistry is studying mutations and responses in myeloproliferative neoplasms (MPNs).

Dr Ian Morison, Professor and Head of the Pathology Department, is focused on genetic determinants of myeloma and how this evolves in Māori and Pasifika.

LBC, with a vision to cure, continues to be firmly committed to funding targeted blood cancer research.



\$476,614

2021-22 financial year investment

\$250,000

Part of the total investment includes money committed to the Leukaemia & Blood Cancer Research Unit at the University of Auckland

Our research to cure remains strong through pandemic challenges

LBC's focus, when it was founded in 1977, was to fund targeted haematology research. This is still a cornerstone of our work today and in the 2021-22 financial year we invested **\$476,614** into a number of different and important blood research initiatives.

This included a further **\$250K** to the "LBCRU" – the Leukaemia & Blood Cancer Research Unit at the University of Auckland. We funded two summer studentships, offering PhD students the opportunity to undertake haematology research and potentially consider this field as their chosen career.

Three significant blood cancer research projects at Otago and Auckland universities were also awarded grants approved by our Medical & Scientific Committee. We also funded the 3rd year of our inaugural John Waller PhD Scholarship.

Included in our funding, was our support for the 2nd year of the Malaghan Institute CAR T-cell trials. Providing travel and accommodation to eligible blood cancer patients ensures equity for everyone to take part in these ground-breaking trials no matter where they may reside in New Zealand.

Listening to the Patient and Whanāu voice


LBC puts patients at the forefront when it comes to planning our support services. We held our annual patient survey to better understand patient and whanāu needs during Covid, to gather feedback on our service, to measure referral needs and to identify any gaps and unmet needs that we could address.

We found several common themes that enabled us to tweak our service provision and adjust things to better meet needs, particularly to address isolation requirements for our vulnerable patients during Covid with improving our online services, expanding our family/whanāu support and increasing our financial support budget.

We also wanted to gauge online vs in-person support preferences to inform our future service strategy in a pandemic world.

LBC's Consumer Advisory Board

For the last 5 years, LBC has had a dedicated consumer advisory board made up of former patients, current patients and family members who are consulted regularly to represent the needs and the voice of patients and whanāu. Our Consumer Advisory Board Impacts Since 2017 are:



Objective

3

Advocacy


#ThisIsBloodCancer

Examples of digital ads from NZ & Australia

In September 2021, we joined forces with our sister organisations from Australia, UK, Canada and the USA to get the message out there for Blood Cancer Awareness Month.

The campaign was built around the central idea of showing people what Blood Cancer is and how it affects people's lives, as well as encouraging people to look for signs of blood cancer in themselves, or their loved ones. Working globally helped deliver a more impactful message.

We take this approach into the future, being part of a global awareness campaign. Delivering content across Instagram, Facebook, LinkedIn and through key news media.



Reach through social media



267,083

1,186



Views of global CEOs' video message



#ThisIsBloodCancer



Taking equity seriously

LBC sees equitable patient/whanāu reach nationwide as a priority. Our team work hard in the hospitals and at health services to connect with Māori and Pacifica health care professionals to ensure good reach to patients across Aotearoa. This year we worked with Te Aho o Te Kahu (Cancer Control Agency) to attend Māori Cancer Community Hui.

We attended all 12 Te Aho Hui around the country which were a great opportunity to present LBC's services. We made important connections with Māori health providers and patients and whanāu, as well as cement relationships with potential referrers.

We were the NGO voice to shine the light on the gaps we fill where the DHBs or the National Travel Assistance scheme fall short.

2021 Winter workshops were a wonderful opportunity for LBC to support and educate health professionals working in the haematology field. In 5 main centres around New Zealand, we held dinner talks with Donna Kerridge on "Understanding Rongoa: the benefits of collaboration". Attendees' feedback was that this was eye opening and important learning to enhance their practice with haematology patients.



Māori medicine practitioner Donna Kerridge

Advocacy in the face of COVID-19

Raising awareness and advocating, to a meaningful level, has regularly been overshadowed by the singular focus of Government and key decision makers on the COVID pandemic. However – a considerable amount of work has continued to highlight and promote the safety and needs of the patients (and their families).

We are a member of the Te Aho o Te Kahu (Cancer Control Agency) Haematology Working Group that meets regularly to provide input into a range of sector reviews, health decisions and challenges within the health sector – which allows us to have direct and recognised influence.

Some of our key focus areas have included:

- Review of Haematology Services in NZ (eg: facilities, workforce, models of care etc)
- Addressing wait times for stem cell transplant treatment (ongoing)
- Vaccination protocols and priorities for patients (COVID)
- Patient priority and access to rapid antigen testing (RATs)
- Access to effective anti-virals for our at risk patients should they contract COVID
- Medical treatments (availability and submissions – as released by Pharmac)
- The Pharmac Review – consultation with the Review Panel and a full submission
- Joint advocacy with other Cancer groups (using the weight of our shared 'voice')

Objective

4

Sustainability

Stepping up to the challenge at Eden Park

For over 100 years, Eden Park has been the home of Auckland rugby and cricket. More recently, the park has opened its doors to different events – and LBC took advantage of this in July 2021 by running the first Step Up Stadium Challenge in Auckland.

It was an ambitious plan to hold a new fundraising event in a year filled with cancellations due to COVID 19.

We knew participants were concerned it may not go ahead. However, not only did it happen but the sun shone on a winter's day, as everyone went up, down and around every stand.

It was a fundraising success as well with over **\$70,000** raised. At the top of the leader board was Wayne Maguire, a long time LBC supporter. Wayne's "Maguire's One Team" fundraised a whopping **\$11,800** with Wayne's personal total sitting at **\$6,000**.

Wayne has been swapping the auctioneer's gavel for some years now. He has climbed the Auckland Sky Tower several times for LBC – including two climbs as part of the non-firefighters squad in the Firefighters Sky Tower Challenge. So, it was no surprise to see him sign up his Ray White Real Estate colleagues to take on a new challenge at Eden Park. A big thank you to Wayne from the LBC team.

\$11,800

Fundraised by Wayne's "Maguire's One Team"



Wayne Maguire

Firefighters climb in dedication – and raised a record total

In May 2021, we held the annual Firefighter Sky Tower Challenge, with 944 firefighters once again taking on the 1103 steps of the Auckland Sky Tower and raising funds for LBC.

This was the 17th climb which is an amazing achievement. What made this one even more special was that our 2020 event had been delayed to November and yet many firefighters were back 6 months later to give it another go. They also raised a record **\$1.35M** supporting patients and families living with blood cancer.

This brings the total raised in 17 years to over **\$10M**. They take part for the challenge and to remember friends, family and workmates impacted by blood and other cancer. As they start their climb, they go around the base of the Sky Tower past the dedication wall filled with photos of loved ones that they have personally chosen and given to LBC.

Peter Fergusson, LBC CEO explains it well “From humble beginnings, this iconic event has now reached the amazing milestone of raising over **\$10m**”.

“ **Most importantly, this mammoth effort has helped tens of thousands of blood cancer patients during the most vulnerable time of their lives, proving that great things do indeed come from small beginnings.** ”



Jimny Clipit turns heads for Shave for a Cure

“ **While Jimny Clipit’s antics drew you in, we were always mindful that the message behind this was the need to support blood cancer patients and families during their cancer journey.** ”



When LBC approached Suzuki NZ for the use of a vehicle to promote our Shave for a Cure campaign, we were delighted to be offered one of the latest Jimnys.

After a radical make-over that included a tangerine mohawk and life-size images on both sides to give the impression you are sitting in a barber’s chair, this eye-catching vehicle was ready to hit the road. And we didn’t stop there! We ran a competition for a name with “**Jimny Clipit**” the clear winner. We organised a competition to guess how many cable ties were used to create the mohawk. And you could follow Jimny Clipit and its adventures on its own Facebook and Instagram pages.

Thanks to Suzuki, we also had prizes for the best photos submitted when you spotted the car on its travels around Auckland and the North Island. It was a lot of fun and it was also an extremely impactful way to raise awareness of the campaign, encouraging more people to register for a shave or to donate to someone else.

Objective

4

Sustainability

Here's to the Shave Heroes of NZ

With unexpected lockdowns throughout the year due to the impact of COVID 19, LBC had to re-think our fundraising events calendar. We realised that one activity you can do wherever you are is shave your hair! So our Shave for a Cure Campaign, previously each March, was transformed into an all year round event with little "mini-campaigns" throughout the year to keep the interest up and the stories flowing.

One of the most successful was our "Shave Heroes" campaign, celebrating those that do extraordinary things and go "the extra mile" to fundraise and to shave for LBC. Some will shave year after year, other do it once and raise an impressive amount – and they all make a massive difference to the blood cancer patients we support.

We didn't have to look hard to find our shave heroes! They included Jenny Bartlett who shaved for the 9th time in 2021 and has no plans to stop. And Aaron Joe, who turned his diagnosis of acute myeloid leukaemia into a huge fundraising opportunity. He persuaded a bunch of mates to form "Team Aaron's Invitational XV", to fundraise together and then all shave their heads.



Jenny Bartlett



Shavee at home



Farmers Shave

“ The Shave Heroes campaign encouraged many more to sign up and support LBC. We finished the year with a record amount of funds raised through Shave for a Cure and intend to repeat the campaign in the coming year. ”

Grant provides TV for day stay patients

LBC prepares over 80 applications annually for Trust grants to support the work that we do. Most of the time we are seeking support for our core work, including salaries for our Support Services staff. However, from time to time, we will also see a need that would increase patient comfort and well-being.

Our Grants Manager will then reach out and apply to a Trust for that specific funding. We were delighted that the Elsie Steele Trust shared our concern that patients in the Haematology Day Stay Unit at Auckland Hospital had nothing to do or watch during the long hours they faced each visit.



Haematology Day Stay Unit Team

“ **Thanks to the Trust, we received a generous grant for a range of items including a new, large television. This was installed in the Unit last year, much to the excitement of the patients and staff.** ”



Aotearoa Charitable Trust supports our Mission to Care

LBC's team of Support Services Coordinators operate from Support Centres throughout the country. The assistance they provide to patients and families impacted by blood cancer and serious blood conditions is at the heart of our organisation's mission to care.


Over the past 12 months, this team has navigated the many challenges faced with the COVID 19 lockdowns and restrictions. With a lack of face-to-face contact, they increased their phone, text and email contact.

They moved their support meetings on-line and also responded to an increase in requests for supermarket and petrol vouchers for those struggling financially. We were delighted when the Aotearoa Gaming Trust (formerly The Southern Trust) provided a substantial grant to cover salaries for members of this team.

The trust was especially keen to support those working with patients in Rotorua, Whakatane, New Plymouth, Levin, Tararua, Christchurch, Waimakariri Dunedin, and Southland.

The Aotearoa Gaming Trust is one of many trusts and foundations that have supported LBC this year with grants to cover core expenditure such as salaries, leases and operational costs.

Having these expenses covered makes a huge difference to our financial stability. We are extremely grateful that they all share our mission to support those facing their blood cancer diagnosis.




Natasha SS team

2021 - 2022


Financial Snapshot

Financial year to 31 March 2022.

Income sources this year



How income was spent this year



Superheroes to the rescue!

When the children at our Hamilton Kids' Clubs decided to invent their own universe with Superheroes fighting cancer, little did they know that their creations would be made into a book!

Thanks to the support and partnership of the PwC Foundation team, who fell in love with the stories and drawings, "The Amazing Outstanding Superheroes" book has been created and printed. Copies are now shared with every child attending our Kids' Clubs across the country. They are also given to the paediatric patients we support.

Kids' Clubs are groups run by LBC to support children aged between 5 and 12 who have a parent or sibling with a blood cancer. They are facilitated by a qualified child play therapist who specialises in fun, safe and friendly workshops for children impacted by cancer. Last year, working around the COVID 19 lockdowns, they were held in Auckland, Hamilton, Wellington and Christchurch.



Once upon a time there was a disease called Cancer. Sprinkle Superhero came along and tried to stop the cancer apocalypse by throwing and shooting rainbow sprinkles. These cure the person of cancer and do not hurt in the process.

We gratefully thank the following trusts and foundations for their generous support

ANZ Staff Foundation
Aotearoa Gaming Trust
Estate of Ernest Hyam Davis and
The Ted & Mollie Carr Endowment Trust
Joyce Fisher Charitable Trust
Lion Foundation
Lottery Community Fund
MSD Community Connection Service
Pub Charity Ltd

Bluesky Community Trust
 Clinton and Joy Whitley Fund with
 Auckland Foundation
 Community Trust South
 David Ellison Charitable Trust
 Eastern and Central Community Trust
 Elsie Steele Trust
 Estate of Gordon Lindsey Isaacs
 Four Winds Foundation
 Freeman Fund (Nikau Foundation)
 Frimley Foundation
 Guy Anson Waddell Charitable Trust
 Helen Graham Charitable Trust

Helen Stewart Royle Charitable Trust
 Higgins Bequest Trust
 Hutt Mana Charitable Trust
 Kiwi Gaming Foundation
 Life Blood Trust
 Louisa and Patrick Emmett Murphy
 Foundation
 Maurice Paykel Charitable Trust
 Mackenzie Charitable Trust
 Milestone Foundation
 MSD Community Food Response Fund
 Nikau Foundation
 Otago Community Trust
 Rata Foundation
 Roy Owen Dixey Charitable Trust
 The Kingdom Foundation
 The Trusts Community Foundation
 Thomas George Macarthy Trust
 Trust House
 Trust Waikato
 W. Duncan Bickley Trust Fund
 Wellington Community Trust

Consolidated statement of comprehensive revenue and expense for the year ended 31 March 2022

	Notes	2022 \$	2021 \$
REVENUE			
Revenue (from exchange transactions)			
Interest and Investment Income		131,718	97,465
Fair Value Gain on investment		6,446	538,813
Revenue (from non-exchange transactions)	7	8,468,699	8,014,480
TOTAL REVENUE		8,606,863	8,650,758
OPERATING EXPENDITURE			
Engagement	8	970,735	971,600
Accountability	8	626,539	590,481
TOTAL OPERATING EXPENDITURE		1,597,274	1,562,081
NET OPERATING SURPLUS BEFORE OUTCOMES		7,009,589	7,088,677
OUTCOMES			
Patient Support, Grant, Research and Advocacy	9	2,905,287	2,500,769
Bone Marrow Tissue Typing , Donor Search and Recruitment	9	3,463,648	3,369,589
TOTAL OUTCOMES		6,368,935	5,870,358
NET SURPLUS FOR THE YEAR		640,654	1,218,319
Other Comprehensive Revenue and Expenses		-	-
TOTAL COMPREHENSIVE REVENUE AND EXPENSES FOR THE YEAR		640,654	1,218,319

The notes attached form part of and should be read in conjunction with these Financial Statements.

Consolidated statement of changes in net assets/equity for the year ended 31 March 2022

	Notes	General Funds			Special Purpose Funds (note 5)		Capital Reserve	Total Net Assets/Equity
		LBC	NZBMDR	Endowment Funds	LBC	Endowment Funds		
		\$	\$	\$	\$	\$	\$	\$
Balance as at April 1 2020		2,354,652	1,086,439	3,135,887	1,089,045	-	235,434	7,901,457
Comprehensive Revenue and Expenses		585,586	332,327	300,406		-	-	1,218,319
New special purpose funds		(100,000)			100,000			-
Transfer from special purpose funds to equity				230,924		(230,924)		-
Transfer from equity to special purpose funds		(25,698)			25,698			-
Payment made from equity					(40,635)		-	40,635
Transfer of equity funds					(710,698)	710,698		-
Balance as at 31 March 2021		2,814,540	1,418,766	3,667,217	463,410	479,774	235,434	9,079,141
Balance as at April 1 2021		2,814,540	1,418,766	3,667,217	463,410	479,774	235,434	9,079,141
Comprehensive Revenue and Expenses		589,859	207,493	(156,698)				640,654
Payment made from equity					(2,812)			(2,812)
Transfer from special purpose funds to equity				250,000				-
Transfer from equity to special purpose funds		(5,000)			5,000	(250,000)		-
Transfer of special purpose funds					(255,000)	255,000		-
Balance as at 31 March 2021		3,399,399	1,626,259	3,760,519	210,598	484,774	235,434	9,716,983

The notes attached form part of and should be read in conjunction with these Financial Statements.

Consolidated statement of financial position as at 31 March 2022

	Notes	2022 \$	2021 \$
NET ASSETS/EQUITY			
General Funds		5,025,658	4,233,306
Endowment Funds		3,760,519	3,667,217
Special Purpose Funds	5	695,372	943,184
Capital Reserve		235,434	235,434
Accumulated Comprehensive Revenue and Expenses		9,716,983	9,079,141
NET ASSETS/EQUITY			
		9,716,983	9,079,141
Represented By:			
CURRENT ASSETS			
Cash & Cash Equivalents	19	2,713,004	2,639,016
Receivables (from exchange transactions)	10	55,009	40,774
Receivables (from non-exchange transactions)	11	509,624	844,380
Donated Assets	12	2,600	44,702
Term Deposits		266,911	264,929
Taxes & Taxation Receivables		25,436	18,180
		3,572,584	3,851,981
NON CURRENT ASSETS			
Investments	16	5,184,952	4,401,506
Property, Plant and Equipment	13	1,917,389	1,953,040
Intangible Assets	14	6,798	12,170
		7,109,139	6,366,716
TOTAL ASSETS		10,681,723	10,218,697
Less:			
CURRENT LIABILITIES			
Trade & Other Payables (from exchange transactions)	17	588,147	780,829
Trade & Other Payables (from non-exchange transactions)	18	372,718	355,674
Taxes & Taxation Payables		3,875	3,053
		964,740	1,139,556
TOTAL LIABILITIES		964,740	1,139,556
NET ASSETS		9,716,983	9,079,141

On behalf of the Trustees



Pene Milne - Chairman
17/08/2022



Andrew McKenzie
17/08/2022

The notes attached form part of and should be read in conjunction with these Financial Statements.

Consolidated statement of cash flows

for the year ended 31 March 2022

	Notes	2022 \$	2021 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Bequest receipts		50,283	406,400
Donations receipts		739,167	638,618
Fundraising donations receipts		3,280,838	2,246,352
Grants receipts		578,222	495,956
MSD Wage subsidies/IRD Resurgence Support		42,536	290,354
Sublease income		22,857	13,596
ADHB contract funding		138,210	138,210
Tissue typing funding and NZ & overseas bone marrow & search receipts		3,767,902	3,541,759
GST(payment) / refund		(6,434)	11,802
Grants paid within New Zealand		(449,139)	(354,502)
Payments to suppliers		(5,111,633)	(4,870,024)
Payments to employees		(2,290,136)	(2,176,328)
		<hr/>	<hr/>
Net cash inflow (outflow) from operating activities		762,673	382,193
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest and Investment income received		128,927	97,110
Receipts from matured investments		-	1,135,079
Payments for purchase of investment		(777,000)	(710,698)
Payments for purchase of fixed assets		(40,612)	(46,532)
		<hr/>	<hr/>
Net cash (outflow) from investing activities		(688,685)	474,959
Net increase in cash and cash equivalents		73,988	857,152
Cash and cash equivalents at beginning of year		2,639,016	1,781,864
		<hr/>	<hr/>
Cash and cash equivalents at the end of year	19	2,713,004	2,639,016

The notes attached form part of and should be read in conjunction with these Financial Statements.

Notes to the consolidated financial statements

for the year ended 31 march 2022

1 STATEMENT OF ACCOUNTING POLICIES

1.1 Reporting entity

Leukaemia & Blood Cancer New Zealand is a Charitable trust under the Charities Act 1957 and is registered as a charitable entity under the Charities Act 2005, and therefore is a public benefit entity for the purposes of financial reporting in accordance with the Financial Reporting Act (2013).

The consolidated financial statements have been prepared for Leukaemia & Blood Cancer New Zealand and its subsidiary, the Leukaemia & Blood Cancer Endowment Fund Trust (collectively referred to as the 'Group'). They are specifically group consolidated financial statements and reflect affairs of the group as a whole.

1.2 Basis of preparation

(a) Statement of compliance

The consolidated statements have been prepared in accordance with New Zealand Generally Accepted Accounting Practice ("NZ GAAP"). They comply with the Public Benefit Entity Accounting Standards Reduced Disclosure Regime ("PBE IPSAS RDR") as appropriate for Tier 2 not-for-profit public benefit entities, for which all reduced disclosure regime exemptions have been adopted.

The Group qualifies as a Tier 2 reporting entity as for the two most recent reporting periods it has had between \$2m and \$30m operating expenditure.

These financial statements were authorised for issue by the trustees on 17 August 2022. The financial statements are prepared in accordance with the Charities Act 2005.

(b) Measurement basis

The financial statements for the Group have been prepared on the basis of historical cost, except for the revaluation of investments to fair value.

(c) Functional and presentation currency

The financial statements are presented in New Zealand dollars (\$) which is the Group's functional and Group's presentation currency. There has been no change in the functional currency of the Group or any significant foreign operations of the Group during the year.

1.3 Use of judgements and estimates

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from those estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

(a) Judgements

Judgements made in applying accounting policies that have had the most significant effects on the amounts recognised in the consolidated financial statements include the following:

- Revenue recognition - non-exchange revenue (conditions vs. restrictions)

The Group's non-exchange revenues include donations, grants and bequests that are recognised when they are received. Where there are conditions attached and a return obligation the revenue is recognised when the conditions have been fulfilled.

(b) Assumptions and estimation uncertainties and a return obligation

There are no estimates that have a significant risk of resulting in a material adjustment in the year ending 31 March 2022.

(c) Changes in accounting estimates

During the period there are no changes in accounting estimates.

1.4 Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these financial statements and have been applied consistently by the Group.

The significant accounting policies of the Group are detailed below:

(a) Basis of consolidation

Subsidiaries are all entities (including special purpose entities) over which the Group has the power to govern the

Notes to the consolidated financial statements for the year ended 31 march 2022

financial and operating policies and are consolidated from the date control is obtained.

In preparing the Group financial statements, all intragroup balances and transactions and unrealised profits arising within the Group are eliminated in full. Investment in the subsidiary is measured at cost and eliminated on consolidation.

(b) COVID-19 Notation

Due to the COVID-19 pandemic (and subsequent outbreaks) there has been considerable economic impact on the New Zealand economy (and globally) arising mainly from Government led actions, including a number of 'lock down' periods and heavy restrictions, where planned income generating events could not take place. Despite these significant challenges - the LBC team were able to re-plan, re-design, recover and increase expected revenue which has improved the organisations financial position.

Management prepared budgets and cash flow forecasts for the period that considered the impact that COVID-19 could have (including the measures put in place by Government) however were able to manage and adjust income channels (and expenses) to achieve improved outcomes. Subsequent to year end, the Group has exceeded budget and events were rescheduled.

The Group has confidence in it's ability to continue to pay all debts when they become due.

(c) Foreign currency

Transactions in foreign currencies are translated to New Zealand dollars at exchange rates at the dates of the transactions.

(d) Special Purpose Fund

Special purpose funds are recognised when funds are received with a specified purpose from the donor, Interest earned on these funds have been included in Interest Received in the Statement of Comprehensive Revenue and Expenses and included in the general funds.

(e) Revenue

Revenue is recognised when the amount of revenue can be measured reliably and it is probable that economic benefits will flow to the Group, and measured at the fair value of consideration received or receivable.

The following specific recognition criteria in relation to the Group's revenue streams must also be met before revenue is recognised.

(i) Revenue from exchange transactions

Interest income received

Interest income is recognised on a time proportion basis using the effective interest rate method.

Fair value gain on investment

Fair value gain on investment is recognised on the fair value of the managed funds provided by the Perpetual Guardian Trust.

(ii) Revenue from non-exchange transactions

Non-exchange transactions are those where the Group received an inflow of resources but provides no (or nominal) direct consideration in return.

Except the revenues from exchange transactions specified in (i), all revenues received in the Group are revenues from non-exchange transactions. The following specific recognition criteria in relation to the Group's non-exchange transaction revenue streams must also be met before revenue is recognised.

Fundraising

The Group's fundraising activities involve event fundraising through website. Fundraising non-exchange revenue is recognised at the point when the funds are received.

Donations, Grants and Bequests

Donations and grants are recognised as revenue at the point when the organisation receives the donations and grants. Where there are conditions attached, the revenue is recognised unless, in the opinion of the board, these conditions have not been fulfilled and there's a return obligation. Income from donations without specific conditions and without an obligation to repay is recognised at the time of receipt.

Bequest revenue and the related receivable are recognised when the entity gains control of the contribution. Control is determined when the undisputed right to receive the contribution is established.

Revenue from tissue typing

NZ Bone Marrow Donor Registry (referred to NZBMDR), a division of the Group is rendering services for donor tissue typing and research. Revenue from the tissue typing and search are recognised as non-exchange revenue.

Notes to the consolidated financial statements for the year ended 31 march 2022

(f) Property, plant and equipment

(i) Recognition and measurement

Items of property, plant, vehicle and equipment are initially measured at cost, except those acquired through non-exchange transactions which are instead measured at fair value as their deemed cost at initial recognition. Cost includes expenditure that is directly attributable to the acquisition of the asset.

(ii) Depreciation

Depreciation is recognised in surplus or deficit on a diminishing value basis to reflect the anticipated usage and obsolescence of the asset.

The DV depreciation rates are:

Computer Equipment & Accessories	26.4% - 48%
Fixtures and fittings	11.4% - 60%
Vehicle	30%
Building	4%

(g) Operating Lease

Lease payments under operating leases where the lessor effectively retains substantially all the rewards and benefits of ownership of the leased item, are charged as expenses in the periods they are incurred.

(h) Investments

Investments are held at fair value through surplus or deficit. Where available, quoted market prices are used as a measure of fair value. Where quoted market prices do not exist, fair values are estimated using present value or other market accepted

(j) Impairment of non-financial assets

The carrying amounts of the Group's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated. There have been no cash generating assets held by the Group during the reporting period.

(k) Financial instruments

The Group initially recognises financial instruments when the Group becomes a party to the contractual provisions of the instrument.

The Group derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability. The Group derecognises a financial liability when its contractual obligations are discharged, cancelled, or expire. The Group also derecognises financial assets and financial liabilities when there have been significant changes to the terms and/or the amount of contractual payments to be received/paid.

Financial assets and liabilities are offset and the net amount presented in the Statement of Financial Position when, and only when, The Group classifies financial assets into the following categories: fair value through surplus or deficit, loans and receivables. The Group classifies financial liabilities into the following categories: fair value through surplus or deficit and amortised cost. Financial instruments are initially measured at fair value, plus for those financial instruments not subsequently measured at fair value through surplus or deficit, directly attributable transaction costs.

Subsequent measurement is dependent on the classification of the financial instrument, and is specifically detailed in the accounting policies below.

(i) Fair value through surplus or deficit

A financial instrument is classified as fair value through surplus or deficit if it is so designated at initial recognition.

If the Group manages such investments and makes purchase and sale decisions based on their fair value in accordance with the Group's documented risk management or investment strategy. Those fair value through surplus or deficit instruments sub-classified as designated at initial recognition comprise investments. Financial instruments classified as fair value through surplus or deficit are subsequently measured at fair value with gains or losses being recognised in surplus or deficit.

(ii) Loans and receivables

Loans and receivables are financial assets with fixed or determinable payments that are not quoted in an active market. After initial recognition these are subsequently measured at amortised cost using the effective interest method, less any impairment losses.

Notes to the consolidated financial statements

for the year ended 31 march 2022

Loans and receivables comprise: cash and cash equivalents, receivables.

Cash and cash equivalents represent highly liquid investments that are readily convertible into a known amount of cash with an insignificant risk of changes in value, with maturities of 3 months or less.

(iii) Amortised cost financial liabilities

Financial liabilities classified as amortised cost are non-derivative financial liabilities that are not classified as fair value through surplus or deficit financial liabilities.

Financial liabilities classified as amortised cost are subsequently measured at amortised cost using the effective interest method. Financial liabilities classified as amortised cost comprise payables.

(l) Impairment of non-derivative financial assets

A financial asset not subsequently measured at fair value through surplus or deficit is assessed at each reporting date to determine whether there is objective evidence that it is impaired. A financial asset is impaired if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset, and that the loss event(s) had an impact on the estimated future cash flows of that asset that can be estimated reliably.

Objective evidence that financial assets are impaired includes default or delinquency by a counterparty, restructuring of an amount due to the Group on terms that the Group would not consider otherwise, indications that a counterparty will enter bankruptcy, adverse changes in the payment status of borrowers, economic conditions that correlate with defaults or the disappearance of an active market for a security. In addition, for an equity security classified as an available-for-sale financial asset, a significant or prolonged decline in its fair value below its cost is objective evidence of impairment.

Financial assets classified as loans and receivables

The Group considers evidence of impairment for financial assets measured at amortised cost (loans and receivables) at both a specific asset and collective level.

All individually significant assets are assessed for specific impairment. Those found not to be specifically impaired are then collectively assessed for any impairment that has been incurred but not yet identified.

Assets that are not individually significant are collectively assessed for impairment by grouping together assets with similar risk characteristics. In assessing collective impairment the Group uses historical trends of the probability of default, the timing of recoveries and the amount of loss incurred, adjusted for management's judgement as to whether current economic and credit conditions are such that the actual losses are likely to be greater or less than suggested by historical trends.

An impairment loss in respect of a financial asset measured at a mortised cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognised in surplus or deficit and reflected in an allowance account against loans and receivables. Interest on the impaired asset continues to be recognised.

When an event occurring after the impairment was recognised causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through surplus or deficit.

2 TAXATION

Leukaemia & Blood Cancer New Zealand is registered as a charitable entity under the Charities Act 2005. It is exempt from income tax.

3 LEASE AND CAPITAL COMMITMENTS

Lease Commitments under Operating Leases

2022	Equipment	Premises
Less than 1 year	3,309	137,052
1 - 2 Years	1,800	83,455
2 - 5 Years	2,707	194,957
5 - 10 Years	-	238,327
2021	Equipment	Premises
Less than 1 year	5,400	142,548
1 - 2 Years	3,309	137,052
2 - 5 Years	4,507	217,012
5 - 10 Years	-	299,727

There were no capital commitments as at the balance date (2021: Nil).

Notes to the consolidated financial statements for the year ended 31 march 2022

4 CONTINGENT LIABILITIES

There were no contingent liabilities as at the balance date (2021: Nil).

5 SPECIAL PURPOSE FUNDS

	2022	2021
	\$	\$
<u>Special Purpose Funds - LBC</u>		
The St Jude's Trust	-	150,000
Angela's Fund	210,598	213,410
Bequest from Pamela Ann Atkinson	-	100,000
	<u>210,598</u>	<u>463,410</u>
<u>Special Purpose Funds - Endowment Fund</u>		
B McClure Fund	319,774	319,774
Bequest from West Legacy	5,000	-
John Waller Fund	110,000	110,000
The St Jude's Trust	50,000	50,000
	<u>484,774</u>	<u>479,774</u>

6 CAPITAL RESERVE

In the past years an amount equivalent to 30% of donations and grants received had been set aside in a capital fund, which Trustees intend to retain as non-distributable capital. In accordance with a decision of the trustees, no transfers have been made since 1988.

7 REVENUE

	Note	2022	2021
		\$	\$
Revenue from non-exchange transactions:			
<i>Donations and goods in-kind received:</i>			
Funds received		739,167	638,618
Donated assets received	12	1,800	4,791
<i>Bequests:</i>			
Bequests received		50,283	406,400
Grants		520,747	463,656
Lottery Community Fund		30,000	30,000
Fundraising		3,281,621	2,384,104
<i>Other funds received:</i>			
MSD Wage subsidies & IRD Resurgence Support		42,536	290,354
Sublease income		22,857	13,596
NZ Patient Bone Marrow Donor Income		3,111,375	2,537,622
Overseas Bone Marrow Search Income		330,947	469,427
HFA Operational Funding		138,210	138,210
HFA Tissue Typing Funding for Bone Marrow Donors		199,156	637,702
		<u>8,468,699</u>	<u>8,014,480</u>

Notes to the consolidated financial statements for the year ended 31 march 2022

8 OPERATING EXPENDITURE	Note	2022	2021
		\$	\$
Engagement		459,785	400,650
Administration		38,903	80,273
Marketing & Consultancy		472,047	490,677
Special Events Expenses		970,735	971,600
Accountability			
Administration		459,784	400,650
Audit Fees - Deloitte		33,166	28,840
Bank Fees & Interest		1,579	1,681
Kiwisaver Employer Contribution		42,743	38,676
Depreciation and Amortisation	13 & 14	81,635	93,230
Lease/ Rent		7,632	7,584
Legal Fees		-	19,820
		626,539	590,481
9 OUTCOMES		2022	2021
		\$	\$
Patient Support, Grant, Research and Advocacy			
Grants and Research		476,614	356,802
Awareness & Advocacy		541,181	485,694
Patient Support		1,887,492	1,658,273
		2,905,287	2,500,769
Bone Marrow Tissue Typing ,Donor Search and Recruitment			
Overseas Bone Marrow Donor Search Expenses		96,499	129,057
Tissue Typing for NZ Bone Marrow Donor Registry		3,186,003	3,067,008
Bone Marrow Donor Recruitment & Matching		181,146	173,524
		3,463,648	3,369,589
10 RECEIVABLES (FROM EXCHANGE TRANSACTIONS)		2022	2021
		\$	\$
Interest receivables		1,090	281
Prepaid expenses		53,919	40,493
		55,009	40,774
11 RECEIVABLES (FROM NON-EXCHANGE TRANSACTIONS)		2022	2021
		\$	\$
Accounts Receivables		373,897	459,588
Sundry Receivables		59,126	90,318
Search Funds on Behalf - see note 20		76,601	294,474
		509,624	844,380

Notes to the consolidated financial statements for the year ended 31 march 2022

12 DONATED ASSETS

Leukaemia & Blood Cancer New Zealand has received a grant from Community Post in goods of 50k DLE postage inclusive envelopes with a value of \$75,000 in November 2019, there were 7k had been used in FY2020 and 14.3k used in FY2021 and the rest used in FY2022. We also have 23x pink jackets donated from Farmers in FY2021 to be given to young patients in the next financial year. In addition, we have received 300 sets RAT kits from Ministry of Health in this financial year to be used for patients and staffs for Covid testing.

13 PROPERTY, PLANT & EQUIPMENT

Cost	Computer equipment	Office equipment	Motor Vehicle	Buildings	Land	Total
	\$	\$	\$	\$	\$	\$
Balance as at 1 Apr 2021	456,366	426,038	17,745	1,532,819	895,000	3,327,968
Additions (exchange)	18,136	18,593	-	3,883	-	40,612
Disposals	-	-	-	-	-	-
Balance as at 31 Mar 2022	474,502	444,631	17,745	1,536,702	895,000	3,368,580
Accumulated depreciation and impairment						
Balance as at 1 Apr 2021	(433,848)	(322,614)	(14,874)	(603,592)	-	(1,374,928)
Depreciation	(15,165)	(23,016)	(861)	(37,221)	-	(76,263)
Impairment	-	-	-	-	-	-
Disposals	-	-	-	-	-	-
Balance as at 31 Mar 2022	(449,013)	(345,630)	(15,735)	(640,813)	-	(1,451,191)
Net book value						
As at 01 Apr 2020	31,025	104,169	4,101	955,633	895,000	1,989,928
As at 31 Mar 2021	22,518	103,424	2,871	929,227	895,000	1,953,040
As at 31 Mar 2022	25,489	99,001	2,010	895,889	895,000	1,917,389

14 INTANGIBLE ASSETS

	Intangible Assets	Total
Cost	\$	\$
Balance as at 1 Apr 2021	587,003	587,003
Additions (exchange)	-	-
Disposals	-	-
Balance as at 31 Mar 2022	587,003	587,003
Accumulated depreciation and impairment		
Balance as at 1 Apr 2021	(574,833)	(574,833)
Depreciation	(5,372)	(5,372)
Impairment	-	-
Disposals	-	-
Balance as at 31 Mar 2022	(580,205)	(580,205)
Net book value		
As at 01 Apr 2020	21,980	21,980
As at 31 Mar 2021	12,170	12,170
As at 31 Mar 2022	6,798	6,798

Notes to the consolidated financial statements for the year ended 31 march 2022

15 RELATED PARTY TRANSACTIONS

(i) Controlling entity and ultimate controlling entity

The controlling and ultimate controlling party of the Group is Leukaemia & Blood Cancer New Zealand. New Zealand Bone Marrow Donor Registry is a division of the Group and Leukaemia Endowment Fund Trust (refer to the Endowment Fund) is a subsidiary of the Group.

(ii) Key management personnel remuneration

The Group classified its key management personnel into the following one of two classes:

a) Members of the board of trustees

b) Senior managers, responsible for the operation of the Group's operating segments, including the Chief Executive Officer.

	2022		2021	
	Remuneration \$	Number of Individuals	Remuneration \$	Number of Individuals
Members of the board of trustees	-	9	-	9
Chief Executive Officer and senior managers*	772,384	6 FTEs	776,936	6 FTEs
	<u>772,384</u>		<u>776,936</u>	

*Senior management remuneration levels have been benchmarked for size and scope using external agencies experts in this area.

(iii) Other related parties

There was no employees who are direct relatives of one of the key management personnel in this financial year (2021: \$ Nil)

16 INVESTMENTS

Leukaemia & Blood Cancer Endowment Fund is a Trust Fund managed by The Perpetual Guardian Trust. The fund holds investments in portfolios within Perpetual Guardian Trust. The principal purpose of the Endowment Fund is to provide sufficient funding to Leukaemia & Blood Cancer New Zealand for research, operational costs or other general purposes.

Investments held at balance date consisted of:

	2022	2021
ASSETS	\$	\$
Perpetual Guardian Managed Funds	5,184,952	4,401,506
Total Investments	<u>5,184,952</u>	<u>4,401,506</u>

17 TRADE AND OTHER PAYABLES (FROM EXCHANGE TRANSACTIONS)

	2022	2021
	\$	\$
Accounts Payable	266,971	536,992
Accruals	321,176	243,837
	<u>588,147</u>	<u>780,829</u>

18 CURRENT TRADE & OTHER PAYABLES (FROM NON-EXCHANGE TRANSACTIONS)

	Note	2022	2021
		\$	\$
Current Grant Liabilities	(a)	280,000	299,080
Grant revenue received in advance		79,197	51,722
Deferred Income		8,500	-
Bone Marrow Donor Search Funds Held on Behalf - see note 20		5,021	4,872
		<u>372,718</u>	<u>355,674</u>

Notes to the consolidated financial statements for the year ended 31 march 2022

18 CURRENT TRADE & OTHER PAYABLES (FROM NON-EXCHANGE TRANSACTIONS) (CONTINUED)

	<u>2022</u>	<u>2021</u>
	\$	\$
(a) Current Grant Liabilities comprise:		
University of Auckland - Research grant to Julie Spicer	-	19,080
University of Auckland - LBC Research Unit	250,000	250,000
University of Auckland - Tissue Bank	30,000	30,000
	<u>280,000</u>	<u>299,080</u>

19 CASH AND CASH EQUIVALENTS

	<u>2022</u>	<u>2021</u>
	\$	\$
Current assets:		
Cash on hand	100	100
Bank deposits	448,463	159,945
Call deposits	2,264,441	2,478,971
Cash and cash equivalents in the statement of cash flows	<u>2,713,004</u>	<u>2,639,016</u>

Per annum annual interest rate ranges applicable to components of cash and cash equivalent:

	<u>2022</u>	<u>2021</u>
Bank deposits	0.05%	0.10%
Call deposits	0.05%	0.10%

In November 2014, Leukaemia & Blood Cancer New Zealand entered into a rolling loan facility with BNZ for a total amount of \$400,000.

As at 31 March 2022, no amounts have been drawn down on this facility (2021: \$Nil).

The loan facility is also secured by a registered first mortgage over the Group's premises at 6 Claude Rd, Epsom.

20 BONE MARROW DONOR SEARCH FUNDS HELD ON BEHALF

The Search Funds held on behalf of patients comprise predominately of funds from New Zealand District Health Boards for worldwide searches of blood and tissue types.

21 SUBSEQUENT EVENTS

There were no material event subsequent to balance date (2021: \$ Nil).

22 FINANCIAL INSTRUMENTS

(i) Classification and fair values of financial instruments

The tables below show the carrying amount of the Group's financial assets and financial liabilities.

Group - 31 March 2022

		Carrying amount (\$)				
		Financial assets		Financial liabilities		
	Note	FVTSD	Loans and receivables	FVTSD	Amortised cost	Total
<i>Subsequently measured at fair value:</i>						
Investment	16	5,184,952				5,184,952
<i>Subsequently not measured at fair value:</i>						
Cash and cash equivalent (assets)	19		2,713,004			2,713,004
Receivables (from exchange transactions)	10		55,009			55,009
Receivables (from non-exchange transactions)	11		509,624			509,624
Trade & Other Payables (from exchange transactions)	17			(588,147)		(588,147)
Trade & Other Payables (from non-exchange transactions)	18			(372,718)		(372,718)
Taxes & Taxation Receivables/(Payables)			25,436			25,436
		<u>5,184,952</u>	<u>3,303,073</u>	<u>-</u>	<u>(960,865)</u>	<u>7,527,160</u>

Notes to the consolidated financial statements for the year ended 31 march 2022

Group - 31 March 2021

		Carrying amount (\$)				
		Financial assets		Financial liabilities		Total
Note		FVTSD	Loans and receivables	FVTSD	Amortised cost	
<i>Subsequently measured at fair value:</i>						
	Investment	16	4,401,506			4,401,506
<i>Subsequently not measured at fair value:</i>						
	Cash and cash equivalent (assets)	19			2,639,016	2,639,016
	Receivables (from exchange transactions)	10			40,774	40,774
	Receivables (from non-exchange transactions)	11			844,380	844,380
	Trade & Other Payables (from exchange transactions)	17			(780,829)	(780,829)
	Trade & Other Payables (from non-exchange transactions)	18			(355,674)	(355,674)
	Taxes & Taxation Receivables/(Payables)				18,180	18,180
			4,401,506	3,542,350	- (1,136,503)	6,807,353



Vision to Cure. Mission to Care.

National Office

PO Box 99182
Newmarket
Auckland 1149

Support Services Centres

Auckland
Hamilton
Wellington
Christchurch
Dunedin

Support Services & General Enquiries
0800 15 10 15

Fundraising & Events
0800 15 15 10